Evommune Looks To Advance Broad Pipeline Of Autoimmune Drugs

 
• By Jessica Merrill

Emerging Company Profile: With experienced leadership and new financing, Evommune is developing a topical IRAK4 inhibitor for atopic dermatitis and earlier-stage systemic drugs for various conditions.

Emerging Company Profile: Evommune
Evommune is developing drugs for inflammatory conditions • Source: Shutterstock

More from Financing

More from Business